| 1353 |
National Cancer Institute |
Html |
en |
Adult Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of adult non-Hodgkin lymphoma |
| indolent lymphoma | 0.429154 |
| PUBMED Ab | 0.422097 |
| mediastinal B-cell lymphoma | 0.454731 |
| Low-grade MALT lymphoma | 0.426029 |
| indolent follicular lymphoma | 0.463176 |
| Engl J Med | 0.422774 |
| International Lymphoma Study | 0.450979 |
| T-cell non-Hodgkin lymphoma | 0.425991 |
| advanced-stage follicular lymphoma | 0.451924 |
| Lymphoma Study Group | 0.535602 |
| large cell lymphoma | 0.468204 |
| peripheral t-cell lymphoma | 0.456381 |
| lymphoid tissue lymphoma | 0.492221 |
| B-cell gastric lymphoma | 0.454154 |
| large b-cell lymphoma | 0.673742 |
| low-grade follicular lymphoma | 0.465805 |
| Clin Lymphoma Myeloma | 0.48896 |
| gastric MALT lymphoma | 0.456031 |
| Follicular Lymphoma International | 0.455402 |
| diffuse large b-cell | 0.567142 |
| anaplastic large-cell lymphoma | 0.485835 |
| nodal follicular lymphoma | 0.485707 |
| Follicular Lymphoma Therapy | 0.460112 |
| marginal-zone B-cell lymphoma | 0.442434 |
| et al. | 0.657474 |
|
| follicular large-cell lymphoma | 0.442424 |
| advanced-stage non-Hodgkin lymphoma | 0.443686 |
| natural killer/t-cell lymphoma | 0.443936 |
| mucosa-associated lymphoid tissue | 0.475564 |
| PUBMED Abstract | 0.461097 |
| diffuse large-B-cell lymphoma | 0.442818 |
| primary follicular lymphoma | 0.490523 |
| low-grade gastric lymphoma | 0.426685 |
| mantle cell lymphoma | 0.422703 |
| follicular lymphoma | 0.604182 |
| Abstract | 0.663115 |
| lymphoplasmacytic lymphoma | 0.440428 |
| Clin Oncol | 0.941 |
| lymphoma | 0.746021 |
| international follicular lymphoma | 0.455144 |
| Low-Grade Lymphoma Study | 0.438252 |
| non-hodgkin lymphoma | 0.449125 |
| marginal zone lymphoma | 0.509105 |
| follicular lymphoma patients | 0.482999 |
| B-Cell Lymphoma Treated | 0.458319 |
| Systemic B-Cell Lymphoma | 0.432957 |
| MALT lymphoma | 0.489467 |
| Non-Hodgkin Lymphoma Study | 0.426008 |
| Lymphoma Classification Project | 0.46454 |
|
CLICK HERE |
| 1476 |
National Cancer Institute |
Html |
en |
Adrenocortical Carcinoma Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of adrenocortical carcinoma. |
| tumor marker | 0.675202 |
| out-of-phase T1-weighted imaging | 0.697012 |
| stage IV tumors | 0.659343 |
| metastatic functioning tumors | 0.801327 |
| staging tool | 0.722476 |
| PDQ cancer information | 0.856921 |
| metastatic lesions | 0.771984 |
| extracapsular tumor invasion | 0.747406 |
| staging systems | 0.691871 |
| potential lung metastasis | 0.731171 |
| adrenocortical carcinomas | 0.63434 |
| chemotherapeutic agent mitotane | 0.781817 |
| cancer information summary | 0.816255 |
| breast cancer prevention | 0.687711 |
| ENSAT staging | 0.713932 |
| mitotane antihormonal drugs | 0.805561 |
| malignant adrenal masses | 0.717902 |
| careful endocrine studies | 0.718613 |
| NCI’s PDQ | 0.665371 |
| PDQ Adult Treatment | 0.724299 |
| Proper staging | 0.693902 |
| NCI PDQ cancer | 0.764668 |
| Adrenal Tumors | 0.670042 |
| effective noninvasive method | 0.696617 |
| adrenal cancer | 0.657663 |
|
| radiation therapy | 0.69704 |
| long-term disease-free survival | 0.704486 |
| complete resection | 0.734805 |
| magnetic resonance imaging | 0.900392 |
| complete tumor resection | 0.779736 |
| excessive hormone production | 0.742148 |
| measurable tumor burden. | 0.740477 |
| steroid receptor antagonists | 0.687573 |
| hormone production | 0.798926 |
| 5-year survival | 0.724946 |
| National Cancer Institute | 0.688962 |
| le Cancer staging | 0.787658 |
| PDQ documents | 0.647653 |
| useful clinical responses | 0.679315 |
| adrenal mass. | 0.63451 |
| World Health Organization. | 0.685412 |
| measurable partial remissions | 0.680413 |
| adrenocortical carcinoma | 0.73628 |
| primary tumor | 0.750316 |
| adjuvant mitotane | 0.712566 |
| above-mentioned AJCC staging | 0.781955 |
| American Joint Committee | 0.694648 |
| regional lymph nodes | 0.695067 |
| Overall 5-year survival | 0.710773 |
|
CLICK HERE |
| 1519 |
National Cancer Institute |
Html |
en |
Rectal Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of rectal cancer. |
| cancer treatment | 0.518883 |
| body | 0.520416 |
| PDQ cancer information | 0.52558 |
| clinical trial search | 0.497998 |
| new blood vessels | 0.485963 |
| Digital rectal exam | 0.48424 |
| clinical trials | 0.752809 |
| nearby lymph nodes | 0.622455 |
| cancer information summary | 0.505272 |
| clinical trial | 0.589481 |
| Rectal Cancer Treatment | 0.502419 |
| colorectal cancer | 0.509773 |
| patients | 0.475547 |
| metastatic rectal cancer | 0.496375 |
| vascular endothelial growth | 0.472356 |
| NCI PDQ cancer | 0.475491 |
| malignant tumor cells | 0.468557 |
| radiation therapy | 0.598557 |
| rectum | 0.694659 |
| treatment | 0.642215 |
| Recurrent rectal cancer | 0.514414 |
| nonpolyposis colorectal cancer | 0.478736 |
| nearby organs | 0.553031 |
| cancer prevention | 0.463023 |
|
| new cancer treatments | 0.468973 |
| NCI-supported cancer | 0.477253 |
| cancer cells | 0.703626 |
| entire rectum | 0.4751 |
| Cancer Information Service | 0.470531 |
| muscle layer | 0.486714 |
| specific cancer cells | 0.477097 |
| endothelial growth factor | 0.47057 |
| treatment clinical trials | 0.482164 |
| National Cancer Institute | 0.505951 |
| outermost layer | 0.501883 |
| new treatment | 0.500006 |
| rectal cancer spreads | 0.494951 |
| Colorectal Cancer section | 0.478726 |
| rectal cancer | 0.877471 |
| rectum wall | 0.683123 |
| Blood. The cancer | 0.463452 |
| cancer research process | 0.463813 |
| cancer clinical trials | 0.522705 |
| stage | 0.526305 |
| tumor | 0.468782 |
| cancer information summaries | 0.468811 |
| comprehensive cancer information | 0.46866 |
| cancer | 0.995137 |
|
CLICK HERE |
| 1809 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de pulmón de células pequeñas (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de pulmón de células pequeñas. |
| Lung Cancer Cooperative | 0.40923 |
| small-cell carcinoma | 0.409726 |
| Arriagada R | 0.406258 |
| mortality from lung | 0.406031 |
| Pignon JP | 0.406568 |
| lung carcinoma | 0.415433 |
| chemotherapy with or | 0.407857 |
| thoracic irradiation | 0.411758 |
| lung cancer | 0.99158 |
| small-cell lung | 0.732567 |
| American Cancer Society | 0.407972 |
| limited-stage small-cell lung | 0.528108 |
| with once-daily thoracic | 0.405556 |
| Cancer Data Base | 0.408315 |
| tobacco-specific lung carcinogen | 0.40968 |
| Lung Oncology Group | 0.405386 |
| Radiat Oncol Biol | 0.407067 |
| Lung Cancer Group | 0.40944 |
| oncology group study | 0.409486 |
| Natl Cancer Inst | 0.413727 |
| Council Lung Cancer | 0.408713 |
| patients with | 0.422455 |
| cancer lung | 0.415587 |
| Does thoracic irradiation | 0.406837 |
| small cell carcinoma | 0.40583 |
|
| small-cell lung carcinoma | 0.412738 |
| childhood cancer | 0.406909 |
| with small-cell lung | 0.428402 |
| Lung Cancer Working | 0.414426 |
| National Cancer | 0.425705 |
| extensive small-cell lung | 0.412452 |
| Clinical Trials Group | 0.406926 |
| small cell lung | 0.507254 |
| National Cancer Institute | 0.418442 |
| prophylactic cranial irradiation | 0.410926 |
| combination chemotherapy with | 0.405558 |
| with combination chemotherapy | 0.405558 |
| National Cancer Data | 0.408383 |
| Clin Oncol | 0.533689 |
| Oncol Biol Phys | 0.407177 |
| combined modality treatment | 0.409248 |
| Low-dose lung | 0.405724 |
| Canada Clinical Trials | 0.406735 |
| treated with | 0.408022 |
| Cancer Working Party | 0.407006 |
| with or without | 0.405778 |
| lung tumours | 0.405564 |
| Cancer Survivor Study | 0.405383 |
| thoracic radiotherapy | 0.433304 |
|
CLICK HERE |
| 2012 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de pulmón (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca de las pruebas utilizadas para detectar o vigilar el cáncer de pulmón. |
| PDQ Exámenes | 0.778524 |
| Physician Data Query | 0.91448 |
| mayores probabilidades | 0.586703 |
| Estados Unidos | 0.865536 |
| rayos x | 0.605899 |
| prevención revisa | 0.573952 |
| PDQ Prevención | 0.807908 |
| siguientes exámenes | 0.801099 |
| principal causa | 0.623129 |
|
| información ayuda | 0.574441 |
| vÃas respiratorias | 0.622976 |
| National Cancer Institute | 0.606892 |
| siguientes riesgos | 0.571899 |
| PDQ Aspectos | 0.723454 |
| siguientes sumarios | 0.714394 |
| Lung Screening Trial | 0.688089 |
| Instituto Nacional | 0.689164 |
|
CLICK HERE |
| 2061 |
National Cancer Institute |
Html |
es |
Mamografías |
Hoja informativa que define las mamografías de detección y de diagnóstico; trata de los beneficios y perjuicios posibles de las mamografías de detección; y resume cómo se reportan los resultados, incluso la densidad de los senos. |
| largo perÃodo | 0.329403 |
| federal affordable care | 0.358034 |
| mamografÃa digital | 0.901811 |
| Database System | 0.32976 |
| de estudios clÃnicos aleatorizados y | 0.369135 |
| técnica especial llamada | 0.347452 |
| programa brinda servicios | 0.346724 |
| posibles limitaciones | 0.337532 |
| rayos x | 0.327782 |
| breast self-exam | 0.336335 |
| CategorÃa Evaluación Seguimiento | 0.350863 |
| posibles perjuicios | 0.338669 |
| alta densidad | 0.339314 |
| tratamiento. Las mamografÃas | 0.58289 |
| pequeñas masas | 0.327877 |
| Exposición a radiación. Las mamografÃas | 0.580742 |
| Resultado benigno | 0.343535 |
| Breast Imaging Reporting | 0.356725 |
| pequeños depósitos de calcio | 0.365542 |
| Colegio Estadounidense | 0.332034 |
| seguro médico | 0.544063 |
|
| mujeres con implantes | 0.382313 |
| detección temprana | 0.693756 |
| Healthcare Research | 0.333438 |
| al feto en crecimiento | 0.333178 |
| casos de carcinoma | 0.332936 |
| Instituto Nacional | 0.371979 |
| Mammography Quality Standards | 0.352873 |
| mujer nota | 0.33784 |
| normales aun | 0.335316 |
| tanta rapidez | 0.335356 |
| usa luz | 0.328978 |
| 3D usa dosis | 0.354905 |
| Requiere biopsia | 0.343563 |
| Estados Unidos | 0.809815 |
| pequeñas de radiación | 0.330854 |
| Cuello Uterino | 0.329522 |
| posibles beneficios | 0.33135 |
| positivos falsos. Los resultados | 0.376938 |
| ley mqsa | 0.332395 |
| decisiones médicas que | 0.334533 |
| mujeres jóvenes | 0.457334 |
|
CLICK HERE |
| 3437 |
National Cancer Institute |
Html |
es |
Prevención del cáncer de estómago (gástrico) (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre factores que pueden influir en el riesgo de presentar cáncer de estómago y sobre las investigaciones dirigidas a la prevención de esta enfermedad. |
| siguientes factores | 0.837019 |
| voluntarios sanos | 0.649737 |
| Physician Data Query | 0.828425 |
| siguientes afecciones | 0.700348 |
| Estados Unidos | 0.992286 |
| suficiente ejercicio | 0.665482 |
| prevención revisa | 0.656327 |
| PDQ Prevención | 0.701412 |
| bacteria helicobacter | 0.66365 |
|
| National Cancer Institute | 0.659684 |
| vitamina c | 0.655742 |
| tipo a | 0.654153 |
| siguientes riesgos | 0.647812 |
| alto contenido | 0.74292 |
| siguientes sumarios | 0.735961 |
| vitamina b12 | 0.670397 |
| Instituto Nacional | 0.708301 |
|
CLICK HERE |
| 3561 |
National Cancer Institute |
Html |
en |
Obesity |
People who are obese may have an increased risk of several types of cancer, whereas eating a healthy diet, being physically active, and keeping a healthy weight may help reduce risk of some cancers. |
| National Heart | 0.499901 |
| Obesity | 0.347906 |
| healthy diet | 0.745052 |
| gallbladder | 0.258317 |
| healthy behaviors | 0.755955 |
| Cancer fact sheets | 0.830969 |
| healthy weight | 0.977177 |
| Physical Activity | 0.512739 |
| Overweight | 0.225819 |
| Blood Institute | 0.497718 |
| kidney | 0.214739 |
|
| uterus | 0.266957 |
| menopause | 0.223953 |
| high blood pressure | 0.86289 |
| heart disease | 0.510853 |
| pancreas | 0.241431 |
| cancers | 0.402713 |
| colon | 0.229687 |
| risk | 0.325352 |
| rectum | 0.279116 |
| information | 0.236001 |
|
CLICK HERE |
| 15638 |
National Cancer Institute |
Html |
null |
Cooperative Agreements |
null |
|
|
CLICK HERE |
| 16847 |
National Cancer Institute |
Html |
en |
Safety of Nanotechnology Cancer Treatment |
Nanotechnology is a powerful tool for combating cancer. NCI's Alliance for Nanotechnology in Cancer is continuously testing the safety of this new technology. |
| nanotech applications | 0.677357 |
| animal models | 0.640611 |
| new technology | 0.654112 |
| tissue damage | 0.64104 |
| cancer therapy | 0.659011 |
| ambient incidental nanoparticles | 0.981236 |
| high reactivity | 0.657801 |
| energy consumption | 0.667996 |
| volcanic ash | 0.655357 |
| small size | 0.652566 |
| nanomaterial safety | 0.671123 |
| NCL works | 0.785834 |
| greenhouse gas emissions | 0.807194 |
| nanomaterials | 0.638465 |
| potential health risks | 0.757642 |
| potential toxicity | 0.657709 |
| industrial applications—have | 0.651915 |
| voluntary-consensus standards | 0.640352 |
| powerful tool | 0.664491 |
| physicochemical properties | 0.648003 |
| available data | 0.647533 |
| NCL | 0.841511 |
| NCL tests | 0.795621 |
| unresolved debate | 0.653791 |
| unique tensile | 0.653407 |
|
| specific type | 0.6502 |
| over-the-counter dandruff remedies | 0.781003 |
| drug carriers | 0.640153 |
| potential risks | 0.643319 |
| Nanotechnology Characterization Laboratory | 0.835959 |
| different nanoparticles | 0.793593 |
| NCI Alliance | 0.651255 |
| order-of-magnitude higher levels | 0.778354 |
| nanoparticle exposure studies | 0.785887 |
| intramural program | 0.646486 |
| background incidental nanoparticles | 0.982807 |
| Stone Age | 0.656862 |
| nanomaterial—carbon nanotubes | 0.650728 |
| cancer applications | 0.701263 |
| human activities | 0.656976 |
| household cleaning products | 0.76545 |
| sea spray | 0.653365 |
| animal studies | 0.647308 |
| cancer research communities | 0.992223 |
| toxicity testing | 0.646545 |
| nanomaterial types | 0.658682 |
| medical applications | 0.642559 |
| magnetic properties | 0.653737 |
| family pets | 0.646993 |
|
CLICK HERE |